Buchumschlag

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Andrea M. Kuczynski, William S. Kingston
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Headache: The Journal of Head and Face Pain
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
von: Kara S. Graves, et al.
Veröffentlicht: (2026)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
von: Yunzhu Tang, et al.
Veröffentlicht: (2025)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
von: Samuel K. Peasah, et al.
Veröffentlicht: (2024)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
von: Alex Harlan, et al.
Veröffentlicht: (2025)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
von: Anna de Dios, et al.
Veröffentlicht: (2024)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
von: Zoe Tasma, et al.
Veröffentlicht: (2025)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
von: Alba López‐Bravo, et al.
Veröffentlicht: (2025)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
von: Joaquín Borrás‐Blasco, et al.
Veröffentlicht: (2025)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
von: Irina Krikova, et al.
Veröffentlicht: (2024)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
von: Marta Pascual‐Mato, et al.
Veröffentlicht: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
von: Jennifer Robblee, et al.
Veröffentlicht: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
von: Tzu‐Hsuan Su, et al.
Veröffentlicht: (2024)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
von: Eric A. Kaiser, et al.
Veröffentlicht: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
von: David Croteau, et al.
Veröffentlicht: (2026)

Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
von: Gabriel Gárate, et al.
Veröffentlicht: (2024)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
von: Ann I. Scher, et al.
Veröffentlicht: (2024)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
von: Andrew C. Charles, et al.
Veröffentlicht: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
von: Chia‐Chun Chiang, et al.
Veröffentlicht: (2024)

The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model
von: Philip Victor Reducha, et al.
Veröffentlicht: (2024)

Evaluating associations of migraine‐related vertigo
von: Nazia Karsan, et al.
Veröffentlicht: (2025)

Genetically proxied liability to migraine and risk of intracranial aneurysm and subarachnoid hemorrhage
von: Iyas Daghlas, et al.
Veröffentlicht: (2024)

Magnetoencephalography studies in migraine and headache disorders: A systematic review
von: Raghavan Gopalakrishnan, et al.
Veröffentlicht: (2024)

Integrating gepants into clinical practice for the acute treatment of migraine
von: Richard B. Lipton, et al.
Veröffentlicht: (2026)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
von: Susan Hutchinson, et al.
Veröffentlicht: (2026)

The association between posttraumatic stress disorder and migraine: A systematic review
von: Lucie Nitsche, et al.
Veröffentlicht: (2026)

Microneedles for the treatment of migraine and orofacial pain: A narrative review
von: Baicheng Cao, et al.
Veröffentlicht: (2026)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
von: Gabriel Camargo de Oliveira, et al.
Veröffentlicht: (2026)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
von: Christopher C. Anderson, et al.
Veröffentlicht: (2024)

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine
von: Christoph T. Berger, et al.
Veröffentlicht: (2026)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
von: Jessica Ailani, et al.
Veröffentlicht: (2024)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
von: Bilal Ahmed Rizvi, et al.
Veröffentlicht: (2024)

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon
von: Stephanie J. Nahas, et al.
Veröffentlicht: (2025)

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review
von: Stephen Silberstein, et al.
Veröffentlicht: (2026)

Migraine is a disorder of function: No evidence for structural alterations within the central nervous system in migraine
von: Jan Mehnert, et al.
Veröffentlicht: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
von: Graham A. McLeod, et al.
Veröffentlicht: (2025)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
von: Andrew Blumenfeld, et al.
Veröffentlicht: (2024)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
von: Richard B. Lipton, et al.
Veröffentlicht: (2025)

Do patients with migraine and obesity receive different treatments? Insights from real‐world data
von: Keshet Pardo, et al.
Veröffentlicht: (2025)

Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
von: Joanna K. Bougie, et al.
Veröffentlicht: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
von: Delora E. Denney, et al.
Veröffentlicht: (2024)